Regulatory update: albiglutide US PDUFA date extended by three months
GSK today announced that the US Prescription Drug User Fee Act (PDUFA) goal date for albiglutide, an investigational once-weekly treatment for adult patients with type 2 diabetes, has been extended by three months.
Issued: London UK
GlaxoSmithKline plc (LSE:GSK) today announced that the US Prescription Drug User Fee Act (PDUFA) goal date for albiglutide, an investigational once-weekly treatment for adult patients with type 2 diabetes, has been extended by three months to 15 April 2014 to provide time for a full review of information submitted by GSK in response to the Food and Drug Administration’s requests.
GSK announced the submission of a Biologics Licence Application to the US FDA for albiglutide on 14 January 2013 and this was followed by the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) on 7 March 2013. The EMA filing is progressing to schedule. Albiglutide is not approved for use anywhere in the world.
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
|
GlaxoSmithKline Enquiries: |
|||
|
UK Media enquiries: |
David Mawdsley |
+44 (0) 20 8047 5502 |
(London) |
|
|
Simon Steel |
+44 (0) 20 8047 5502 |
(London) |
|
|
David Daley |
+44 (0) 20 8047 5502 |
(London) |
|
|
Catherine Hartley |
+44 (0) 20 8047 5502 |
(London) |
|
|
|
|
|
|
US Media enquiries: |
Stephen Rea |
+1 215 751 4394 |
(Philadelphia) |
|
|
Kevin Colgan |
+1 919 483 2933 |
(North Carolina) |
|
|
Melinda Stubbee |
+1 919 483 2510 |
(North Carolina) |
|
|
Mary Anne Rhyne |
+1 919 483 0492 |
(North Carolina) |
|
|
Sarah Alspach |
+1 202 715 1048 |
(Washington, DC) |
|
|
Jennifer Armstrong |
+1 215 751 5664 |
(Philadelphia) |
|
|
|||
|
Analyst/Investor enquiries: |
Ziba Shamsi |
+ 44 (0) 20 8047 3289 |
(London) |
|
Lucy Budd |
+44 (0) 20 8047 2248 |
(London) |
|
|
Tom Curry |
+ 1 215 751 5419 |
(Philadelphia) |
|
|
Gary Davies |
+ 44 (0) 20 8047 5503 |
(London) |
|
|
James Dodwell |
+ 44 (0) 20 8047 2406 |
(London) |
|
|
Jeff McLaughlin |
+ 1 215 751 7002 |
(Philadelphia) |
Cautionary statement regarding forward-looking statements |
